Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
PHGE Quote, Financials, Valuation and Earnings
Last price:
$6.33
Seasonality move
:
-17.34%
Day range:
$4.06 - $4.87
52-week range:
$1.50 - $14.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
18.03x
Volume:
50.3K
Avg. volume:
2M
1-year change:
-61.67%
Market cap:
$7.4M
Revenue:
--
EPS (TTM):
-$23.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHGE
BiomX, Inc.
|
-- | -$5.06 | -- | -66.65% | $399.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.70 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
NUWE
Nuwellis, Inc.
|
$2.3M | -- | 9.98% | -- | $13.00 |
|
PRCT
PROCEPT BioRobotics Corp.
|
$93.7M | -$0.32 | 16.65% | -23.05% | $32.50 |
|
STAA
STAAR Surgical Co.
|
$75.1M | $0.17 | 64.85% | 39.51% | $22.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHGE
BiomX, Inc.
|
$4.87 | $399.00 | $7.4M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.50 | $31.70 | $3.8B | 9.83x | $0.00 | 0% | 3.56x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.65 | $457.00 | $42.3B | 141.18x | $0.00 | 0% | 11.45x |
|
NUWE
Nuwellis, Inc.
|
$1.43 | $13.00 | $9.9M | -- | $0.00 | 0% | 0.38x |
|
PRCT
PROCEPT BioRobotics Corp.
|
$26.26 | $32.50 | $1.5B | -- | $0.00 | 0% | 4.73x |
|
STAA
STAAR Surgical Co.
|
$18.92 | $22.73 | $934M | 49.73x | $0.00 | 0% | 4.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHGE
BiomX, Inc.
|
1071.64% | 1.269 | 6.69% | 0.78x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
NUWE
Nuwellis, Inc.
|
8.91% | -1.025 | 1.64% | 1.20x |
|
PRCT
PROCEPT BioRobotics Corp.
|
17.66% | 1.070 | 4.46% | 5.64x |
|
STAA
STAAR Surgical Co.
|
9.96% | -0.104 | 2.95% | 4.10x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHGE
BiomX, Inc.
|
-$1.2M | -$7.2M | -159.8% | -235.09% | -- | -$4.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
NUWE
Nuwellis, Inc.
|
$1.4M | -$2.7M | -773.58% | -1004.06% | -121.65% | -$3.2M |
|
PRCT
PROCEPT BioRobotics Corp.
|
$46.3M | -$31M | -20.6% | -24.85% | -40.64% | -$12.2M |
|
STAA
STAAR Surgical Co.
|
$76.6M | $44.5M | -23.38% | -25.83% | 46.96% | $1.8M |
BiomX, Inc. vs. Competitors
-
Which has Higher Returns PHGE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of 96.33%. BiomX, Inc.'s return on equity of -235.09% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital PHGEBiomX, Inc.-- -$8.37 $134K ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About PHGE or ACAD?
BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 3288.09%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.70 which suggests that it could grow by 40.89%. Given that BiomX, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe BiomX, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHGEBiomX, Inc.1 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is PHGE or ACAD More Risky?
BiomX, Inc. has a beta of 1.676, which suggesting that the stock is 67.593% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock PHGE or ACAD?
BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHGE or ACAD?
BiomX, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. BiomX, Inc.'s net income of -$13.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 3.56x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGEBiomX, Inc.-- -- -- -$13.3M ACADACADIA Pharmaceuticals, Inc.3.56x 9.83x $284M $273.6M
-
Which has Higher Returns PHGE or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of 16.99%. BiomX, Inc.'s return on equity of -235.09% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital PHGEBiomX, Inc.-- -$8.37 $134K ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About PHGE or ALNY?
BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 3288.09%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 43.42%. Given that BiomX, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe BiomX, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHGEBiomX, Inc.1 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is PHGE or ALNY More Risky?
BiomX, Inc. has a beta of 1.676, which suggesting that the stock is 67.593% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock PHGE or ALNY?
BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHGE or ALNY?
BiomX, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. BiomX, Inc.'s net income of -$13.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 11.45x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGEBiomX, Inc.-- -- -- -$13.3M ALNYAlnylam Pharmaceuticals, Inc.11.45x 141.18x $1.1B $186.4M
-
Which has Higher Returns PHGE or NUWE?
Nuwellis, Inc. has a net margin of -- compared to BiomX, Inc.'s net margin of 21.11%. BiomX, Inc.'s return on equity of -235.09% beat Nuwellis, Inc.'s return on equity of -1004.06%.
Company Gross Margin Earnings Per Share Invested Capital PHGEBiomX, Inc.-- -$8.37 $134K NUWENuwellis, Inc.65.18% $0.56 $4.3M -
What do Analysts Say About PHGE or NUWE?
BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 3288.09%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 32207.73%. Given that Nuwellis, Inc. has higher upside potential than BiomX, Inc., analysts believe Nuwellis, Inc. is more attractive than BiomX, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHGEBiomX, Inc.1 0 0 NUWENuwellis, Inc.0 1 0 -
Is PHGE or NUWE More Risky?
BiomX, Inc. has a beta of 1.676, which suggesting that the stock is 67.593% more volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.263%.
-
Which is a Better Dividend Stock PHGE or NUWE?
BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHGE or NUWE?
BiomX, Inc. quarterly revenues are --, which are smaller than Nuwellis, Inc. quarterly revenues of $2.2M. BiomX, Inc.'s net income of -$13.3M is lower than Nuwellis, Inc.'s net income of $468K. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 0.38x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGEBiomX, Inc.-- -- -- -$13.3M NUWENuwellis, Inc.0.38x -- $2.2M $468K
-
Which has Higher Returns PHGE or PRCT?
PROCEPT BioRobotics Corp. has a net margin of -- compared to BiomX, Inc.'s net margin of -39.07%. BiomX, Inc.'s return on equity of -235.09% beat PROCEPT BioRobotics Corp.'s return on equity of -24.85%.
Company Gross Margin Earnings Per Share Invested Capital PHGEBiomX, Inc.-- -$8.37 $134K PRCTPROCEPT BioRobotics Corp.60.63% -$0.53 $444.4M -
What do Analysts Say About PHGE or PRCT?
BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 3288.09%. On the other hand PROCEPT BioRobotics Corp. has an analysts' consensus of $32.50 which suggests that it could grow by 23.76%. Given that BiomX, Inc. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe BiomX, Inc. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PHGEBiomX, Inc.1 0 0 PRCTPROCEPT BioRobotics Corp.7 3 0 -
Is PHGE or PRCT More Risky?
BiomX, Inc. has a beta of 1.676, which suggesting that the stock is 67.593% more volatile than S&P 500. In comparison PROCEPT BioRobotics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHGE or PRCT?
BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. PROCEPT BioRobotics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHGE or PRCT?
BiomX, Inc. quarterly revenues are --, which are smaller than PROCEPT BioRobotics Corp. quarterly revenues of $76.4M. BiomX, Inc.'s net income of -$13.3M is higher than PROCEPT BioRobotics Corp.'s net income of -$29.8M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while PROCEPT BioRobotics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 4.73x for PROCEPT BioRobotics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGEBiomX, Inc.-- -- -- -$13.3M PRCTPROCEPT BioRobotics Corp.4.73x -- $76.4M -$29.8M
-
Which has Higher Returns PHGE or STAA?
STAAR Surgical Co. has a net margin of -- compared to BiomX, Inc.'s net margin of 9.38%. BiomX, Inc.'s return on equity of -235.09% beat STAAR Surgical Co.'s return on equity of -25.83%.
Company Gross Margin Earnings Per Share Invested Capital PHGEBiomX, Inc.-- -$8.37 $134K STAASTAAR Surgical Co.80.89% $0.18 $392.9M -
What do Analysts Say About PHGE or STAA?
BiomX, Inc. has a consensus price target of $399.00, signalling upside risk potential of 3288.09%. On the other hand STAAR Surgical Co. has an analysts' consensus of $22.73 which suggests that it could grow by 20.11%. Given that BiomX, Inc. has higher upside potential than STAAR Surgical Co., analysts believe BiomX, Inc. is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings PHGEBiomX, Inc.1 0 0 STAASTAAR Surgical Co.1 9 1 -
Is PHGE or STAA More Risky?
BiomX, Inc. has a beta of 1.676, which suggesting that the stock is 67.593% more volatile than S&P 500. In comparison STAAR Surgical Co. has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.569%.
-
Which is a Better Dividend Stock PHGE or STAA?
BiomX, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. STAAR Surgical Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BiomX, Inc. pays -- of its earnings as a dividend. STAAR Surgical Co. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHGE or STAA?
BiomX, Inc. quarterly revenues are --, which are smaller than STAAR Surgical Co. quarterly revenues of $94.7M. BiomX, Inc.'s net income of -$13.3M is lower than STAAR Surgical Co.'s net income of $8.9M. Notably, BiomX, Inc.'s price-to-earnings ratio is -- while STAAR Surgical Co.'s PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BiomX, Inc. is -- versus 4.08x for STAAR Surgical Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGEBiomX, Inc.-- -- -- -$13.3M STAASTAAR Surgical Co.4.08x 49.73x $94.7M $8.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
